6OQY

Human LRH-1 bound to the agonist 6N and a fragment of the Tif2 coregulator

6OQY の概要

• エントリーDOI: 10.2210/pdb6oqy/pdb
• 分子名称: Nuclear receptor subfamily 5 group A member 2, Nuclear receptor coactivator 2, N-[(1S,3aR,6aR)-5-hexyl-4-phenyl-3a-(1-phenylethenyl)-1,2,3,3a,6,6a-hexahydropentalen-1-yl]sulfuric diamide, ... (4 entities in total)
• 機能のキーワード: nuclear hormone receptor, agonist, transcription
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 30605.39

構造登録者

Mays, S.G.,Ortlund, E.A. (登録日: 2019-04-29, 公開日: 2019-08-28, 最終更新日: 2023-10-11)

主引用文献

Mays, S.G.,Flynn, A.R.,Cornelison, J.L.,Okafor, C.D.,Wang, H.,Wang, G.,Huang, X.,Donaldson, H.N.,Millings, E.J.,Polavarapu, R.,Moore, D.D.,Calvert, J.W.,Jui, N.T.,Ortlund, E.A.
Development of the First Low Nanomolar Liver Receptor Homolog-1 Agonist through Structure-guided Design.
J.Med.Chem., 62:11022-11034, 2019

PubMed Abstract: As a key regulator of metabolism and inflammation, the orphan nuclear hormone receptor, liver receptor homolog-1 (LRH-1), has potential as a therapeutic target for diabetes, nonalcoholic fatty liver disease, and inflammatory bowel diseases (IBD). Discovery of LRH-1 modulators has been difficult, in part due to the tendency for synthetic compounds to bind unpredictably within the lipophilic binding pocket. Using a structure-guided approach, we exploited a newly discovered polar interaction to lock agonists in a consistent orientation. This enabled the discovery of the first low nanomolar LRH-1 agonist, one hundred times more potent than the best previous modulator. We elucidate a novel mechanism of action that relies upon specific polar interactions deep in the LRH-1 binding pocket. In an organoid model of IBD, the new agonist increases expression of LRH-1-controlled steroidogenic genes and promotes anti-inflammatory gene expression changes. These studies constitute major progress in developing LRH-1 modulators with potential clinical utility.

PubMed: 31419141
DOI: 10.1021/acs.jmedchem.9b00753

実験手法

X-RAY DIFFRACTION (2.23 Å)